PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies


Tekesin K., Akar E., Gunes M. E. , Bayrak S., ÖZTÜRK T. , Altinay S., ...More

JOURNAL OF BUON, vol.24, no.5, pp.1920-1926, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 5
  • Publication Date: 2019
  • Title of Journal : JOURNAL OF BUON
  • Page Numbers: pp.1920-1926

Abstract

Purpose: The purpose of this study was to retrospectively investigate the response to trastuzumab in breast cancer patients in terms of the potential roles of several oncogenic pathways (phosphatase and tensin homolog (PTEN) and phosphatidylinositol 3-kinase (PI3K)) in relation to HER2 status.